BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/25/2015 11:25:00 AM | Browse: 1173 | Download: 1702
 |
Received |
|
2015-06-02 10:06 |
 |
Peer-Review Started |
|
2015-06-04 19:11 |
 |
To Make the First Decision |
|
2015-06-18 15:08 |
 |
Return for Revision |
|
2015-06-30 17:08 |
 |
Revised |
|
2015-07-16 15:50 |
 |
Second Decision |
|
2015-09-21 17:48 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2015-09-30 18:46 |
 |
Articles in Press |
|
2015-09-30 18:47 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2015-12-10 09:01 |
 |
Publish the Manuscript Online |
|
2015-12-24 17:39 |
ISSN |
1949-8462 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Cardiac & Cardiovascular Systems |
Manuscript Type |
Minireviews |
Article Title |
Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications
|
Manuscript Source |
Invited Manuscript |
All Author List |
Stavros Spiliopoulos and Georgios Pastromas |
Funding Agency and Grant Number |
|
Corresponding Author |
Stavros Spiliopoulos, MD, PhD, EBIR, Department of Interventional Radiology, Patras University Hospital, Ippokratous Avenue, 26504 Rio, Greece. stavspiliop@upatras.gr |
Key Words |
Coronary disease; Clopidogrel; Aspirin; High on treatment platelet reactivity; Peripheral arterial disease; Antiplatelet therapy; Ticagrelor; Prasugrel |
Core Tip |
Recent data related high on-treatment platelet reactivity (HTPR) with adverse clinical outcomes, such as stent thrombosis and repeat procedures, following coronary or peripheral endovascular revascularization procedures. Notably, the incidence of patients suffering from peripheral arterial disease demonstrating inadequate response to clopidogrel is around 50%, which is much higher than the approximately 30% reported for patients suffering from coronary artery disease. Novel more potent antiplatelet P2Y12 agents seem to overcome the phenomenon of HTPR decreasing ischemic events with the cost of increased bleeding risk. Until today no major trial demonstrated clinical improvement for patients undergoing platelet function test-guided individualized antiplatelet therapy. Prescription of new antithrombotic agents aims in avoiding major cardiovascular adverse events, as well as sustaining vessel patency following revascularization. Therefore, improving antiplatelet therapy, considering the risk/benefit ratio, is imperative especially in HTPR patients. Further large-scale studies are awaited to elucidate the role of individualized therapy. |
Publish Date |
2015-12-24 17:39 |
Citation |
Spiliopoulos S, Pastromas G. Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications. World J Cardiol 2015; 7(12): 912-921 |
URL |
http://www.wjgnet.com/1949-8462/full/v7/i12/912.htm |
DOI |
http://dx.doi.org/10.4330/wjc.v7.i12.912 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345